Home

WESEEYOUâ„¢

Intercept’s commitment to research is a commitment to you

The advances we are making in the development of novel treatments for liver diseases such as primary biliary cirrhosis (PBC) and nonalcoholic steatohepatitis (NASH) have the potential to change the lives of patients and physicians who currently have few, if any, therapeutic options.

LEARN ABOUT PBC AND NASH >

News

Monday, April 13, 2015

Intercept Announces New Data in PBC and NASH to be Presented at EASL 2015
See the press release >